Wound mg't co Polyheal sees positive interim results

The Clal Biotechnology portfolio company is studying patients in Israel with chronic wounds.

Clal Biotechnology Industries Ltd. (TASE: CBI) portfolio company Polyheal Ltd. today announced positive interim results for its Polyheal-1 product for the treatment of chronic wounds. The double-blind clinical trial includes 60 patients at five medical centers in Israel.

Polyheal is developing a novel microsphere-based wound care technology to facilitate active wound healing products for chronic skin ulcers, burns, trauma, and post-surgical wounds. The product has already obtained EU CE Mark certification.

The interim results are based on an analysis of the results on 30 patients. The study found statistically significant results that Polyheal-1 is effective and met all the primary and secondary objectives of the trial of monitoring the healing process of the wound and its closure. The study also found no significant side effects.

On the basis of the results, Polyheal will continue the clinical trial as planned.

CBI, a unit of Nochi Dankner's IDB Holding Corp. Ltd. (TASE:IDBH) through Clal Industries and Investments Ltd. (TASE: CII), owns 35% of Polyheal. The company's other investors are Challenge Fund - Etgar, Polar Investments Ltd. (TASE: PLR) unit Koonras Technologies Ltd., Technorov Holdings (1993) Ltd., and LN Technology Innovations Ltd.

Published by Globes [online], Israel business news - www.globes-online.com - on February 22, 2009

© Copyright of Globes Publisher Itonut (1983) Ltd. 2009

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018